U.S. markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.87 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.45 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.52
    -0.01 (-0.02%)
     
  • Gold

    1,790.70
    +2.60 (+0.15%)
     
  • Silver

    22.77
    +0.14 (+0.60%)
     
  • EUR/USD

    1.1955
    +0.0041 (+0.35%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • GBP/USD

    1.3336
    -0.0020 (-0.15%)
     
  • USD/JPY

    103.9700
    -0.2800 (-0.27%)
     
  • BTC-USD

    18,262.21
    +494.15 (+2.78%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.41 (+0.40%)
     

Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the grant to 266 new employees of inducement stock options to purchase an aggregate of 33,040 shares of its common stock and restricted stock units for an aggregate of 267,729 shares of its common stock under its 2019 Inducement Award Plan. The stock options are exercisable at a price of $15.81 per share, the closing price of Intra-Cellular Therapies’ common stock on March 30, 2020, the grant date. The stock options and restricted stock units were granted as inducements material to each employee’s acceptance of employment with Intra-Cellular Therapies in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has a 10-year term. Each stock option and restricted stock unit vests in a series of three equal annual installments on each anniversary of the grant date over a three-year period, subject to the employee’s continued service with Intra-Cellular Therapies through the applicable vesting dates. The stock options and restricted stock units are subject to the terms and conditions of Intra-Cellular Therapies’ 2019 Inducement Award Plan, and the terms and conditions of equity award agreements covering the grants.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies affect the inner-workings of cells in the body. The Company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Contact

Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Lisa Burns
jgrimaldi@burnsmc.com
212-213-0006

MEDIA INQUIRIES:

Ana Fullmer
Corporate Media Relations W2Owcg
afullmer@wcgworld.com
202-507-0130